Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline

키워드

참고문헌 (66)

1. Ju-Yeon Cho, "Management of liver diseases during the pandemic of coronavirus disease-19", Clinical and Molecular Hepatology, 26(3), pp.243~250 (2020), 대한간학회[DOI]
2. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
3. Wang Y, "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19", J Hepatol, 73, pp.807~816 (2020)
4. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
5. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
6. Zhang C, "Liver injury in COVID-19 : management and challenges", Lancet Gastroenterol Hepatol, 5, pp.428~430 (2020)
7. Xu L, "Liver injury during highly patho genic human coronavirus infections", Liver Int, 40, pp.998~1004 (2020)
8. Bikdeli B, "COVID-19 and thrombotic or thromboembolic disease : implications for prevention, antithrombotic therapy, and follow-up : JACC state-of-the-art review", J Am Coll Cardiol, 75, pp.2950~2973 (2020)
9. Paranjpe I, "Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19", J Am Coll Cardiol, 76, pp.122~124 (2020)
10. Song Jeong Eun, "Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment", Gut and Liver, 15(4), pp.606~615 (2021), 거트앤리버 소화기연관학회협의회[DOI]
11. Williamson EJ, "Factors associated with COVID-19-related death using OpenSAFELY", Nature, 584, pp.430~436 (2020)
12. Singh S, "Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States : a multicenter research network study", Gastroenterology, 159, pp.768~771 (2020)
13. Lens S, "SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain", J Hepatol, 73, pp.1262~1263 (2020)
14. Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease : US multi-center study", Clin Gastroenterol Hepatol, 19, pp.1469~1479 (2021)
15. Marjot T, "SARS-CoV-2 infection in patients with autoimmune hepatitis", J Hepatol, 74, pp.1335~1343 (2021)
16. Moon AM, "High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis : preliminary results from an international registry", J Hepatol, 73, pp.705~708 (2020)
17. Bajaj JS, "Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone : multicentre matched cohort", Gut, 70, pp.531~536 (2021)
18. Park JG, "Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19 : a retrospective multicentre cohort study", BMJ Open, 10, pp.e041989~ (2020)
19. Yu Rim Lee, "Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea", Clinical and Molecular Hepatology, 26(4), pp.562~576 (2020), 대한간학회
20. Mahmud N, "Declining cirrhosis hospitalizations in the wake of the COVID-19 pandemic : a national cohort study", Gastroenterology, 159, pp.1134~1136 (2020)
21. D’Antiga L, "Coronaviruses and immunosuppressed patients : the facts during the third epidemic", Liver Transpl, 26, pp.832~834 (2020)
22. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
23. Colmenero J, "Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients", J Hepatol, 74, pp.148~155 (2021)
24. Webb GJ, "Outcomes following SARS-CoV-2 infection in liver transplant recipients : an international registry study", Lancet Gastroenterol Hepatol, 5, pp.1008~1016 (2020)
25. RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
26. Gerussi A, "Coronavirus disease 2019(COVID-19)in autoimmune hepatitis : a lesson from immunosuppressed patients", Hepatol Commun, 4, pp.1257~1262 (2020)
27. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
28. Goldman JD, "Remdesivir for 5 or 10 days in patients with severe Covid-19", N Engl J Med, 383, pp.1827~1837 (2020)
29. Beigel JH, "Remdesivir for the treatment of Covid-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
30. Sarges P, "Drug-induced liver injury : highlights from a review of the 2015 literature", Drug Saf, 39, pp.801~821 (2016)
31. Kullak-Ublick GA, "Drug-induced liver injury : recent advances in diagnosis and risk assessment", Gut, 66, pp.1154~1164 (2017)
32. "Administration and management of Veklury (remdesivir) for medical facilities (ver. 07)"[URL]
33. Montastruc F, "Hepatic disorders with the use of remdesivir for coronavirus 2019", Clin Gastroenterol Hepatol, 18, pp.2835~2836 (2020)
34. Saviano A, "Liver disease and coronavirus disease 2019 : from pathogenesis to clinical care", Hepatology, 74, pp.1088~1100 (2021)
35. Stone JH, "Efficacy of tocilizumab in patients hospitalized with Covid-19", N Engl J Med, 383, pp.2333~2344 (2020)
36. Björnsson ES, "Hepatotoxicity by drugs : the most common implicated agents", Int J Mol Sci, 17, pp.224~ (2016)
37. REMAP-CAP Investigators, "Interleukin-6 receptor antagonists in critically Ill patients with Covid-19", N Engl J Med, 384, pp.1491~1502 (2021)
38. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
39. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)", Clin Infect Dis, 71, pp.732~739 (2020)
40. Joyner MJ, "Safety update : COVID-19 convalescent plasma in 20, 000hospitalized patients", Mayo Clin Proc, 95, pp.1888~1897 (2020)
41. Shen C, "Treatment of 5critically Ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
42. Fang L, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection", Lancet Respir Med, 8, pp.e21~ (2020)
43. Vaduganathan M, "Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19", N Engl J Med, 382, pp.1653~1659 (2020)
44. Guo J, "Coronavirus disease 2019(COVID-19)and cardiovascular disease : a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors", angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, 2020, pp.9, e016219~
45. "COVID-19 vaccination guideline (helathcare personnel)"[URL]
46. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
47. "Phase III double-blind, placebo-controlled study of AZD1222 for the prevention of COVID-19 in adults"[URL]
48. Marjot T, "SARS-CoV-2 vaccination in patients with liver disease : responding to the next big question", Lancet Gastroenterol Hepatol, 6, pp.156~158 (2021)
49. "Janssen. FDA Briefing Document:Johnson &Johnson/Janssen COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting"[URL]
50. "Reports of cerebral venous sinus thrombosis with thrombocytopenia after Janssen COVID-19 vaccine"[URL]
51. "AstraZeneca vaccine: timeline of what’s happened since European countries suspended use of Covid jab"[URL]
52. Furie KL, "Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia", Stroke, 52, pp.2478~2482 (2021)
53. Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
54. Hunter PR, "Thrombosis after covid-19 vaccination", BMJ, 373, pp.n958~ (2021)
55. Notarnicola A, "Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies", Scand J Rheumatol, 52, pp.390~397 (2021)
56. "Guidance: covid-19 vaccination and blood clotting"[URL]
57. Bonnel AR, "Immune dysfunction and infections in patients with cirrhosis", Clin Gastroenterol Hepatol, 9, pp.727~738 (2011)
58. Bonazzi PR, "Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list", Braz J Infect Dis, 12, pp.306~309 (2008)
59. Pascasio JM, "Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation", Transplant Proc, 40, pp.2943~2945 (2008)
60. Cornberg M, "EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients", J Hepatol, 74, pp.944~951 (2021)
61. Fix OK, "Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic : AASLD expert panel consensus statement", Hepatology, 72, pp.287~304 (2020)
62. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
63. Swadling L, "Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection", Vaccines(Basel), 4, pp.27~ (2016)
64. Kelly C, "Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans", Hepatology, 63, pp.1455~1470 (2016)
65. "Recommendation on COVID-19 vaccination in transplant patients"[URL]
66. Fix OK, "American Association for the Study of Liver Diseases expert panel consensus statement : vaccines to prevent coronavirus disease 2019infection in patients with liver disease", Hepatology, 74, pp.1049~1064 (2021)

관련 논문AI추천